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ABSTRACT 
 
Macrophages are able to differentiate into classically polarized (M1) or alternatively polarized 
(M2) states upon encountering pro-inflammatory cytokines such as interferon (IFN)  or anti-
inflammatory cytokines such as interleukin (IL) -4/IL-13, respectively. Moreover, macrophages 
are known to regulate lipid metabolism via multiple members of the nuclear hormone receptor 
family, including the retinoid X receptors (RXR). It has been also documented that cytokines are 
able to modulate macrophage responses to lipid signals but the nature of these interactions and 
the underlying mechanisms of these processes especially at the level of the chromatinized 
genome are not well understood. Previous work from our laboratory suggested that STAT6 is a 
facilitator of nuclear receptor mediated transcriptional activity acting at the genome level. This 
prompted us to investigate genome-wide DNA binding events and the development of cistromes 
in human CD14+ monocyte-derived macrophages upon exposure to IL-4. We determined the 
impact of IL-4 on the PU.1, RXR and STAT6 cistromes within the active enhancer regions 
marked by H3K27-acetylation using chromatin immunoprecipitation followed by deep 
sequencing and integrated bioinformatics analyses. We found that about 2/3rd of the IL-4 induced 
STAT6 peaks co-localized with RXR peaks.  These STAT6/RXR co-peaks differed at least in 
part from the non-overlapping RXR peaks regarding the most enriched de novo transcription 
factor binding motifs. Interestingly, RXR-binding was not regulated at the STAT6/RXR co-
bound enhancers following IL-4 stimulation, but differential enhancer interactions were observed 
between the IL-4/STAT6 and RXR signaling pathways acting in a gene selective manner. Our 
results suggest that there is a novel, so far uncharacterized cistromic crosstalk between RXR and 
STAT6 that is likely to contribute to the formation of the active enhancer repertoire, 
transcriptome and differential signal-specific gene regulation of polarized macrophages. 
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BACKGROUND 
 
Macrophages are immune cells that take part in both the initiation as well as the resolution phase 
of inflammation, depending on the surrounding cytokine milieu. If macrophages are exposed to 
inflammatory cytokines such as interferon (IFN) gamma or tumor necrosis factor (TNF) alpha 
then classically polarized (aka M1) cells form, while anti-inflammatory cytokines such as 
interleukin (IL) -4 or IL-13 give rise to alternatively polarized (M2) macrophages (Gordon and 
Taylor, 2005,Lawrence and Natoli, 2011,Murray and Wynn, 2011). 
Cytokines bind to their respective receptors that, among other signaling pathways, allow the 
activation of Janus tyrosine kinases (JAK), subsequently leading to the phosphorylation, 
dimerization and nuclear translocation of Signal Transducer and Activator of Transcription 
(STAT) proteins (Darnell, Kerr and Stark, 1994,Leonard, 2001). For instance, IL-4/IL-13 via 
JAK2 activate STAT6, a transcription factor that is known to directly bind a unique gamma 
activated sequence (GAS) motif with a 4 nucleotides spacer TTC(N)4GAA (Ehret, Reichenbach, 
Schindler et al., 2001,Schindler, Wu, Rothe et al., 1995) leading to the regulation of genes 
responsible for cell proliferation, survival and immune function (Gordon and Martinez, 2010). 
Myeloid cells including dendritic cells and macrophages are also unique in their ability to sense 
and respond to lipids in their environment and translate these signals into transcriptional changes 
via certain members of the nuclear hormone receptor family including the Peroxisome 
Proliferator Activated Receptors (PPAR), Liver X Receptors (LXR), Vitamin D receptor (VDR) 
and Retinoic Acid Receptors (RAR) in heterodimers with Retinoid X Receptors (RXR) (reviewed 
in (Kiss, Czimmerer and Nagy, 2013)). In the absence of ligands RXR heterodimers are generally 
bound to DNA to act as transcriptional repressors by recruiting nuclear receptor corepressor 
(NCoR) or silencing mediator of retinoid and thyroid receptors (SMRT)-containing corepressor 
complexes (Watson, Fairall and Schwabe, 2012,McKenna, Lanz and O'Malley, 1999). On the 
other hand, ligand activation induces corepressor/coactivator complex exchange and 
consequently transcriptional activation of nuclear hormone receptor target genes (McKenna et al., 
1999,Kato, Yokoyama and Fujiki, 2011). Based on the activation properties of its ligands, RXR 
heterodimers can be categorized as permissive or non-permissive. Permissive RXR heterodimers 
including PPAR/RXR or LXR/RXR- can be activated by the ligands of either partner. In contrast, 
non-permissive heterodimers cannot be activated by an RXR agonist but only of the dominant 
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partner receptors such as VDR or RAR (Germain, Chambon, Eichele et al., 2006). These RXR 
heterodimers are responsible for the development of important functional characteristics 
including lipid metabolism and inflammatory responsiveness in different macrophage 
polarization states (reviewed in (Kiss et al., 2013,Varga, Czimmerer and Nagy, 2011)). In 
addition, liganded RXR promotes a unique gene expression program resulting in the elevated 
expression of pro-angiogenic genes and enhanced angiogenic activity in macrophages (Daniel, 
Nagy, Hah et al., 2014).  
Besides the thorough investigation of the physiological consequences of cytokine and/or lipid 
signals in macrophages it is also important to understand the underlying epigenomic events such 
as transcription factor DNA binding as well as chromatin modifications as determinants of 
transcriptional and consequently phenotypic and functional outcomes (Lawrence and Natoli, 
2011). For example, in mouse macrophages it is already known how cytokine stimuli via 
genomic binding events and histone posttranslational modifications induce transcriptional 
changes to shape macrophage activity (Lawrence and Natoli, 2011,Ostuni, Piccolo, Barozzi et al., 
2013). Furthermore, important genomic and cistromic aspects, such as epigenetic enhancer 
signatures (Pham, Benner, Lichtinger et al., 2012), PU.1 binding (Pham, Minderjahn, Schmidl et 
al., 2013), transcriptome mapping upon M-CSF, GM-CSF (Beyer, Mallmann, Xue et al., 2012) or 
various stimuli (Xue, Schmidt, Sander et al., 2014) in human CD14+ monocyte-derived 
macrophages have also been reported. 
It is also known that the macrophage polarization signals and nuclear hormone receptor signaling 
can interact with each other to modulate macrophage phenotype and functions. Among the 
potential RXR heterodimerization partners, PPARȖ expression and activity is tightly regulated by 
different macrophage polarization stimuli (Huang, Welch, Ricote et al., 1999,Szanto, Balint, 
Nagy et al., 2010,Nagy, Czimmerer, Szanto et al., 2013). IL-4-activated STAT6 acts as a 
facilitator of PPARȖ signaling during alternative macrophage activation (Szanto et al., 2010). In 
contrast, TNFα and IFNȖ-induced classical macrophage activation is associated with repressed 
PPARȖ activity in both human and murine cells (Szanto et al., 2010,Nagy et al., 2013). The 
importance of RARs in alternative macrophage activation pertaining to the ability of these cells 
to reversibly and dynamically alter their phenotypes upon the continously changing tissue 
environment was recently highlighted by the finding that all-trans retinoic acid is involved in the 
functional polarization of peritoneal macrophages via the reversible up-regulation of the GATA6 
 5 
transcription factor (Okabe and Medzhitov, 2014). It has also been described that LXR activation 
modulates the functional properties of human alternatively polarized macrophages (Bories, Colin, 
Vanhoutte et al., 2013). Little is known, however, of the molecular details of IL-4 and RXR 
signaling crosstalk at the epigenomic and gene expression levels to shape macrophage function. 
These pieces of evidence prompted us to investigate the epigenomic events that take place in 
these cells upon IL-4 stimulation and RXR activation. In the present work we have assessed how 
IL-4 modulates the human STAT6 cistrome in primary human CD14+ monocyte-derived 
differentiating macrophages. Moreover, we sought to understand how the IL-4 induced STAT6 
cistrome and the baseline RXR cistrome might interact with one another within the context of 
active macrophage enhancers marked by the H3K27Ac histone modification and the macrophage 
lineage specific factor, PU.1. To this end, we have performed ChIP with antibodies to H3K27Ac, 
PU.1, RXR and STAT6 from cells left unstimulated or stimulated with IL-4. We carried out an 
integrated bioinformatic analysis of the data sets and established the overlapping peak sets 
between PU.1, RXR and STAT6. Surprisingly, we found that approximately 2/3rd of the STAT6 
peaks overlapped with RXR/PU.1 peaks but these were not associated with nuclear receptor (NR) 
half sites sufficiently similar to be found enriched with motif analysis tools, suggesting that (i) 
these RXR peaks likely differ from those not overlapping with STAT6, and/or (ii) RXR might be 
indirectly recruited to these regions. Furthermore, the STAT6/RXR/PU.1 co-peaks associated 
with distinct transcription factor motifs than the PU.1/RXR co-peaks, including those of RUNX 
and C/EBP factors, suggesting that STAT6 is recruited to genomic  frequented by several factors 
(Siersbaek, Nielsen, John et al., 2011). Lastly, we have confirmed the differential interactions 
between IL-4/STAT6 and RXR signaling pathways by means of eRNA transcript quantification 
on a select set of target genes. 
Our data revealed a novel interrelationship between the RXR and STAT6 cistromes, further 
strengthening the notion that lipid and cytokine signals converge in macrophages and thus our 
results contribute important details to the ever expanding field of immune and metabolic cross-
regulation. 
 
MATERIALS AND METHODS 
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Monocyte isolation and differentiation, cell culture and treatments: Human monocytes were 
isolated from peripheral blood mononuclear cells (PBMC) of healthy volunteers. Buffy coats 
were obtained from the Regional Blood Bank. Monocyte separation was carried out using CD14 
MicroBeads (Miltenyi Biotec) according to the manufacturer’s instructions. Monocytes were 
cultured and differentiated to macrophages by their attachment to cell culture plate in RPMI 1640 
supplemented with 10% FBS, 2 mM glutamine, penicillin and streptomicyn for the indicated 
time. (Liu, Shi, Huang et al., 2008,Perlman, Pagliari, Georganas et al., 1999,Pagliari, Perlman, 
Liu et al., 2000,Liu, Perlman, Pagliari et al., 2001) Cells were stimulated as indicated with IL-4 
(20 ng/ml) for the time specified within the figure legends. LG268 was used at 100 nM final 
concentrations, respectively for the time indicated in the figure legends. DMSO-Ethanol served 
as vehicle control (0.01%). 
 
Chromatin immunoprecipitation and ChIP library preparation:  Human CD14+ monocyte-
derived differentiating macrophages at 24 hours following isolation were treated with IL-4 (20 
ng/ml, 30 min) as indicated then harvested by scraping in medium followed by centrifugation at 
4C for 10 min at 1000 g then cross-linked using DSG and formaldehyde-based double cross-
linking method and processed for ChIP. Chromatin was immunoprecipitated with antibodies 
against PU.1 (sc-352), STAT6 (sc-981), RXR (sc-774) and H3K27Ac (ab4729). Library 
preparation and analysis were performed as previously described (Nagy, Daniel, Jonas et al., 
2013) with minor modifications. 1 ng (STAT6, PU.1, RXR) and 5 ng (H3K27Ac) DNA amounts 
were used for the library preparation. 
 
ChIP-seq analysis: The primary analysis of raw sequence reads has been carried out using our 
ChIP-seq_analyze command line pipeline (Barta, 2011). Alignment to the hg19 genome assembly 
was made by the Burrows-Wheeler Alignment (BWA) tool (Li and Durbin, 2009). Genome 
coverage (bedgraph) files were made by makeUCSCfile.pl (Homer) (Heinz, Benner, Spann et al., 
2010) and used for visualization with IGV 2.3 (Thorvaldsdottir, Robinson and Mesirov, 2013). 
EBI PeakSplitter (Bertone Group Software) was used for obtaining regions occupied by 
H3K27ac modified histones as described in (Nagy et al., 2013) with minor modifications. The 
thus predicted regions of the vehicle and IL-4 treated samples were extended by 0.5 kb in both 
directions and then merged (BEDtools) (Quinlan and Hall, 2010). Transcription factor ChIP-seq 
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peaks were predicted by Homer findPeaks (p<0.0001), and false enrichments according to our 
homemade blacklist and those do not exceed 3 RPKM read density were eliminated. Consensus 
peak sets for PU.1, RXR and STAT6 were determined by DiffBind: Two biological replicates for 
both experimental condition (control and IL-4 treatment) were used; and those peaks that could 
be predicted from at least any two of four samples were merged and regarded as consensus peaks  
(Ross-Innes, Stark, Teschendorff et al., 2012). For further analyses peaks overlapping with the 
H3K27ac modified regions were used. Peak set overlaps were defined by intersectBed 
(BEDTools) and visualized by VennMaster-0.37.5 (Kestler, Muller, Gress et al., 2005). 
Annotations and read distribution histograms centered to peaks were made by annotatePeaks.pl 
(Homer). Read distribution heat maps were created by Java TreeView in log2 scale from the 
output of annotatePeaks.pl. Summit +/-100 bp of all or the top 1000 peaks (based on the highest 
Homer peak score of the merges) was used for the prediction of motif enrichments by 
findMotifsGenome.pl (Homer). Repeat masking and 10, 12, 14 and 16 search length were set. 
Target percent refers to the ratio of the peaks having the given motif, and background (Bg) 
percent shows the motif enrichment of a large random sequence collection with 200-base lengths. 
P-values were calculated based on the enrichments of these two sets of regions. The used 
command line scripts are available upon request. 
 
RNA-Seq: Indexed cDNA libraries were prepared from 1 µg of total RNA following the 
TruSeq™ RNA Sample Preparation Kit (Illumina, Inc.) protocol. Briefly, the mRNA Poly-A was 
selected on oligo (dT) magnetic beads and fragmented by divalent cations at 94°C for 5 min. 
Reverse transcription was performed using SuperScript II reverse transcriptase (Life 
Technologies, Inc.) and random primers. After second strand cDNA synthesis, fragments were 
end repaired, A-tailed and ligated with indexed adapters. cDNA libraries were purified and size 
selected after PCR with AMPure XP beads (Beckman Coulter, Inc, Fullerton, C.A USA). The 
average size of inserts was 1γβ±17 bp. The 100 bp paired-end sequencing of the cDNA libraries 
was performed on pools of 4 samples in equal ratio in a single lane of the Illumina Hiseq 2500 
sequencer. Quality criteria were checked during the run (Q30, base distribution, error rate, etc.). 
Raw images were processed for base calling and fastq files went through a quality check pipeline 
(duplication rate, coverage, number of genes/transcripts, etc.). The TopHat-Cufflinks-Cuffdiff 
toolkit trio (Trapnell, Hendrickson, Sauvageau et al., 2013) was used for mapping spliced reads, 
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making transcript assemblies. Downstream data analyses were performed in R (Team, 2013). Bar 
plots and clustering were created using R packages ggplot2 and stats, respectively (Kolde, 2013). 
 
Real-Time Quantitative PCR for enhancer RNA and mRNA detection (qPCR): RNA was isolated 
with Trizol reagent (Ambion). RNA was reverse transcribed with High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) according to manufacturer’s protocol. Transcript 
quantification was performed by qPCR reactions using SYBR green master mix (BioRad). 
Transcript levels were normalized to GAPDH. Primers are available upon request. 
 
RESULTS AND DISCUSSION 
 
Investigation of IL-4-modulated gene expression signature in primary human monocyte-
derived differentiating macrophages.  
 
In order to investigate the potential interaction between IL-4/STAT6 and RXR signaling in 
human differentiating macrophages (diffMQ), we induced the differentiation of human peripheral 
blood-derived CD14+ monocytes to macrophages by their attachment to the cell culture plate. 
First, we validated the experimental cell model as depicted in Figure 1A by testing IL-4 
responsiveness using RNA-seq methodology to confirm that the cells were able to differentiate 
towards the M2 phenotype (Figure 1B). We observed that following IL-4 treatment 826 genes 
showed a minimum of 1.5 fold differences including the previously described IL-4-induced 
alternative macrophage activation markers MRC1, SOCS1, MAOA, TGM2, SLA, CD180 and 
ENPP2 in both donors (Figure 2A and B) (Gordon and Martinez, 2010,Czimmerer, Varga, 
Poliska et al., 2012,Martinez, Helming, Milde et al., 2013). Next, we aimed to determine, which 
biological processes were affected in diffMQ cells by IL-4. Using DAVID Bioinformatics 
Database (Huang da, Sherman and Lempicki, 2009), we found that the IL-4-regulated genes were 
associated with inflammation and lymphocyte chemotaxis-linked biological processes (Figure 
2C). Next, we determined the expression levels of RXR isoforms and their potential 
heterodimerization partners in unstimulated and IL-4 stimulated diffMQ cells using our RNA-seq 
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data set. In agreement with the previously published studies (Roszer, Menendez-Gutierrez, 
Cedenilla et al., 2013), two out of three RXR isoforms such as RXRα and RXRȕ were expressed 
(RPKM≥1 at least one diffMQ sample) in our experimental cell model (Figure 2D). In addition, 9 
potential RXR heterodimerization partners were also expressed at least one human donor-derived 
unstimulated diffMQ cells including the most abundantly expressed LXRα, LXRȕ, PPARδ, VDR 
and RARα (Figure 2D). Finally, the M2-type polarization-mediated regulation of three nuclear 
receptors was observed in both human donors-derived diffMQ cells including the IL-4-induced 
PPARȖ and VDR as well as the repressed LXRα (Figure 2D).     
These data demonstrate that the ex vivo-derived diffMQ cells were likely polarized toward the 
M2 phenotype following IL-4 treatment and expressed two RXR isoforms and several of their 
heterodimerization partners.  
 
Mapping PU.1, RXR and STAT6 occupied enhancer regions in human CD14+ monocyte-
derived differentiating macrophages. 
 
In order to gain insight into how IL-4 driven cistromic changes relate to macrophage and/or lipid 
mediated genomic events in diffMQ cells, first we differentiated macrophages  from human 
peripheral blood-dervied CD14+ monocytes  and performed  ChIP-seq studies, as depicted in 
Figure 1 A and B.  
In this set of experiments we identified chromatin regions that harbor the active enhancer mark, 
histone 3 acetylated at lysine 27 (H3K27Ac) (Creyghton, Cheng, Welstead et al., 2010) as well as 
genomic binding regions of the myeloid lineage-specific macrophage pioneer factor PU.1 
(Simon, Olson, Scott et al., 1996,Friedman, 2007,Ghisletti, Barozzi, Mietton et al., 2010), the 
IL4-driven transcription factor STAT6 and the lipid mediated transcription factor RXR. Next, we 
comparatively analyzed the genomic data sets using integrated bioinformatic tools as described in 
the Materials and Methods. As shown in Figure 3A, 20,046 PU.1 (75% of 26,531 total), 12,799 
(90% of 14,125) RXR and 1,417 (93% of 1,573) STAT6 peaks were found positive for the 
H3K27Ac active enhancer mark. The Venn diagram also represents the overlap among the peaks 
occupied by these transcription factors (TFs): approximately 75% of RXR peaks and 80% of 
STAT6 peaks fell within regions positive for PU.1 (~7,600 and ~1,200, respectively). 
Intriguingly, about 60% of STAT6 peaks overlapped with RXR peaks (~1,000), a phenomenon 
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which, to our knowledge, has not yet been reported in the scientific domain for these two factors 
(Figure 3A and B). On the other hand, PU.1 binding sites in relation to those of PPARG/RXR in 
Thp-1 cells (Pott, Kamrani, Bourque et al., 2012) or PPARG in mouse thioglycolate-elicited 
macrophages (Lefterova, Steger, Zhuo et al., 2010) were also found to overlap approximately at 
60%, which is in good correlation with our results. 
Next, we examined the IL-4-modulated binding of RXR, PU.1 and STAT6 transcription factors 
at the H3K27Ac and PU.1 double-positive genomic regions (Figure 3B). First, it should be 
emphasized that according to the current dogma STATs only become phosphorylated, dimerize 
and translocate to the nucleus to bind DNA upon cytokine stimulation (Darnell et al., 
1994,Leonard, 2001). In line with this, STAT6 peaks (blue) only occur in the IL-4 treated 
samples but not in unstimulated cells as shown in Figure 3B. PU.1 (red) is known to 
constitutively occupy enhancers in mouse macrophages (Ghisletti et al., 2010), which is in 
agreement with our results in these cells. So far, genomic RXR binding sites were mapped during 
mouse adipogenesis (Nielsen, Pedersen, Hagenbeek et al., 2008,Hamza, Pott, Vega et al., 2009), 
in mouse osteoblast cells (Meyer, Goetsch and Pike, 2010) and in the human monocytic cell line, 
Thp-1 (Pott et al., 2012). In addition, a previous study from our laboratory described the 
constitutive  baseline landscape of RXR binding in unstimulated mouse bone marrow derived 
macrophages (Daniel et al., 2014), strengthening our findings.  However, the effect of a short 
term treatment with IL-4 (30 min) has not yet been published in any human macrophage system; 
hence the baseline constitutive in vivo kinetics of RXR DNA binding (green) observed in the 
present work could not be supported by independent earlier results.  
Finally, we investigated the IL-4-mediated effects on H3K27Ac enrichment at the RXR, STAT6 
and RXR+STAT6 co-bound H3K27Ac and PU.1 double-positive genomic regions in IL-4 
stimulated and unstimulated diffMQ cells (Figure 3C). IL-4-induced H3K27Ac enrichment was 
observed at both STAT6 and RXR/STAT6 co-bound genomic regions, however, both basal and 
IL-4-enhanced H3K27 acetylation were lower at the STAT6 bound genomic regions compared to 
the RXR/STAT6 co-bound genomic sites (Figure 3C). These findings suggest the IL-4-dependent 
activation of both STAT6 and RXR+STAT6 co-bound regulatory elements in diffMQ cells.  
 
Genomic distribution and motif analysis of PU.1, RXR and STAT6 occupied regions. 
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As the next step, we classified the location of the peaks relative to coding genes. We established 
the following categories: promoter-TSS, 5' UTR, exon, intron, 3' UTR, TTS, non-coding and 
intergenic (Figure 4A). We found that PU.1 peaks localized to promoter-TSS, intronic and 
intergenic regions at 13, 44 and 37%, respectively; while RXR peaks localized to promoter-TSS, 
intronic and intergenic regions at 24, 35 and 34%, respectively. On the other hand, STAT6 peaks 
were distributed between introns and intergenic regions at 42 and 49%, respectively. In light of 
the significant overlap between RXR and STAT6 peaks, it was not surprising that the 
RXR/STAT6 co-peaks were at a similar extent split between these two major categories (41 and 
49%). The genomic localization of STAT6 examined in mouse or human Th2 cells was 59% or 
51% intergenic, respectively; in good agreement with our findings (Elo, Jarvenpaa, Tuomela et 
al., 2010,Wei, Vahedi, Sun et al., 2010). 
 
Next, we analyzed the consensus motifs under the ChIP-Seq peaks identified using the HOMER 
toolkit ((Hamza et al., 2009), see Matherial and Methods) (Figure 4B). First, the top 2000 peaks 
of PU.1 and RXR were analyzed. The most significantly enriched motifs for PU.1 were PU.1 and 
C/EBP, while nuclear receptor (NR) half sites, PU.1, C/EBP followed by DR4, AP-1, DR1 and 
REL were found for RXR. The latter list was compiled using de novo motif search. Then, the 
overlapping peaks between PU.1 and RXR were analyzed for the top 1000 PU.1 peaks, which 
harbored enriched PU.1 motifs, and the same held true for the top RXR peaks within this peak 
set, followed by the C/EBP, DR4, AP-1 and NR half sites. The appearance of DR4 is intriguing 
and may suggest that in this type of cell RXR might act by heterodimerizing with partner(s) 
preferentially bound to this motif, such as LXR. In agreement with this finding, LXRα and ȕ 
were the most abundantly expressed RXR heterodimerization partners in differentiating human 
macrophages (Figure 2D). PU.1 and STAT6 shared approximately 300 peaks, in which category 
the PU.1 motif was also the most significantly enriched one, followed by the STAT6 consensus 
motif then the CCAAT/enhancer-binding protein (C/EBP) and Activator Protein (AP) -1 motifs. 
The proximity of AP-1 and C/EBP sites to PU.1 sites was already demonstrated in mouse 
macrophages (Heinz et al., 2010,Lefterova et al., 2010). Surprisingly, when testing the enhancers 
marked by all three factors, even the forced motif search  failed to reveal potential binding sites 
for RXR, suggesting that (i) RXR recruitment to these regions could be indirectly mediated (i.e. 
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independently from direct RXR DNA binding) or (ii) RXR might recognize non-canonical 
binding sites. 
 
Determination of the interactions between IL-4/STAT6 and RXR signaling pathways in 
differentiating macrophages. 
 
In order to investigate whether the lipid sensing RXRs can influence IL-4/STAT6 signaling 
pathway-mediated transcriptional changes in diffMQ cells, we annotated the RXR and STAT6 
peaks to IL-4-regulated genes. We found that 26% of STAT6 and 29% of RXR+STAT6 co-peaks 
were observed within ±100 Kb distance from TSSs of IL-4-regulated genes (Figure 5A). In 
addition, 16% of RXR peaks were also associated with IL-4 responsive genes (Figure 5A). 
Interestingly, the distribution of the annotated peaks relative to TSS is fairly symmetrical in all 
the three peak sets (Figure 5B). Next, we decided to determine how the ligand-activated RXR 
signaling pathway can modulate IL-4-induced transcriptional events at the gene expression level 
in diffMQ cells. We selected 7 IL-4-activated and RXR/STAT6 co-bound enhancer-associated 
genes including well characterized alternative macrophage activation markers and immune-
modulator genes (Gordon and Martinez, 2010,Czimmerer et al., 2012,Martinez et al., 
2013,Colotta, Saccani, Giri et al., 1996,Scotton, Martinez, Smelt et al., 2005), and analyzed the 
IL-4-dependent induction of their expression at the mRNA level in the presence or absence of the 
synthetic RXR ligand LG268 using RT-QPCR (Figure 5C).  Interestingly, 3 out of the 7 selected 
genes including CCL26, IL1RN and FCER2 were not regulated by LG268 alone, but their IL-4-
induced expression levels were enhanced in the presence LG268 compared to the IL-4 and 
vehicle-treated diffMQ cells suggesting the potentiating role of ligand-activated RXR in this 
process (Figure 6A). Our previous findings documented the existence of an extensive crosstalk 
between the IL-4-activated STAT6 and the synthetic PPARȖ ligand rosiglitazone-activated 
permissive RXR/PPARȖ heterodimers in human and mouse alternatively polarized macrophages 
(Szanto et al., 2010). However, 2 out of 3 LG268 facilitated genes such as IL1RN and CCL26 
expression were not regulated in unstimulated and IL-4-stimulated human monocyte-derived 
differentiating macrophages by rosiglitazone (Szanto et al., 2010). These findings suggest that the 
liganded RXR-mediated potentiation of IL1RN and CCL26 expression was a permissive 
RXR/PPARȖ heterodimer-independent process in IL-4 treated diffMQ cells. In addition, IL-4-
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activation of STAT6 and the rosiglitazone-activation of PPARȖ transcription factors had an 
additive effect on the gene expression level of FCER2 in human differentiating macrophages 
(Szanto et al., 2010). Interestingly, we found that ligand activation of RXR could enhance 
FCER2 expression in the presence of IL-4 suggesting, that (i) FCER2 expression is regulated by 
non-canonical RXR/PPARȖ permissive heterodimer or (ii) this process might be PPARȖ 
independent. The well established alternative macrophage polarization marker and nuclear 
receptor target gene TGM2 was induced in both IL-4 and LG268-stimulated cells and its 
expression level was synergistically induced in co-treated cells (Figure 6A) (Daniel et al., 
2014,Martinez et al., 2013,Rebe, Raveneau, Chevriaux et al., 2009,Nagy, Saydak, Shipley et al., 
1996). Similar synergistic interaction was observed between IL-4/STAT6 and ligand-activated 
PPARȖ signaling pathways in the case of several PPARȖ target genes  such as FABP4 and PDK4 
in human differentiating macrophages (Szanto et al., 2010). However, TGM2 was not induced by 
rosiglitazone suggesting, that the synergistic crosstalk between IL-4/STAT6 and liganded RXR 
signaling pathways was not impacted by liganding PPARȖ (Szanto et al., 2010). It is not clear 
though if the presence of the receptor (PPAR) was required.  It has been reported that TGM2 is a 
direct target gene of RXR/RAR signaling pathway in human and mouse macrophages (Rebe et 
al., 2009,Nagy et al., 1996). Although, RARs are known as non-permissive heterodimerization 
partners of RXRs, but we observed the induction of TGM2 expression and activation of TGM2-
associated enhancers in mouse macrophages by both RXR and RAR-specific synthetic agonists 
(Daniel et al., 2014). These results raised the possibility that non-canonical permissive RXR/RAR 
heterodimers can regulate TGM2 expression. However the RXR/RAR hetrodimer’s participation 
in the IL-4 and LG268-medited synergistic induction of TGM2 expression remains to be 
determined. Finally, we found that the basal and IL-4-induced expression of 3 selected genes 
such as CLEC4G, CD209 and CISH were not regulated by LG268 suggesting (i) the existence of 
non-permissive heterodimer-dependent regulatory mechanisms or (ii) their insensitivity for 
nuclear receptor ligands (Figure 6A).     
 Next, we wanted to investigate whether the crosstalk between the ligand-activated RXR and IL-
4/STAT6 signaling pathways is also observed at the selected IL-4 responsive genes-associated 
RXR/STAT6 co-bound enhancers. It has been recently described that enhancer RNA (eRNA) 
expression is a suitable marker of enhancer activity (Natoli and Andrau, 2012,Simandi, Horvath, 
Nagy et al., 2016,Daniel, Nagy and Nagy, 2014). Therefore, we measured the IL-4 and/or 
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LG268-modulated eRNA expression at 6 selected enhancers by RT-QPCR. We detected the IL-4-
induced activation of eRNA expression at all selected enhancers, but the RXR ligand-induced 
modulation of IL-4 responsiveness was distinct and only partially overlapped if compared to the 
mRNA expression (Figure 6B). The potentiating role of LG268 on IL-4 responsiveness was 
detected at CCL26_-6,5Kb and IL1RN_-13Kb enhancers similarly to mRNA expression (Figure 
6B). In addition, the synergistic action of LG268 and IL-4 was also observed at the TGM2_3,3Kb 
enhancer (Figure 6B). The IL-4 and LG268-dependent co-regulation of eRNA expression at the 
above examined RXR-STAT6 co-peak-bound enhancers raises the possibility of an extensive 
interactions between RXR and STAT6 transcription factors including liganded RXR-facilitated 
STAT6 binding or co-activator recruitment. However, the investigation of the molecular bases of 
synergistic and potentiating interactions between RXR and STAT6 requires further analysis. 
Interestingly, unlike in the case of FCER2 mRNA expression, LG268 did not enhance the IL-4-
induced eRNA expression at FCER2_-2,3Kb enhancer (Figure 6B). However, FCER2 gene was 
associated with other RXR-bound regulatory region (Figure 5C) suggesting that the complex 
interaction of several RXR and STAT6 bound enhancers likely contribute to the synthetic RXR 
ligand-dependent potentiation of IL-4-induced FCER2 expression. Finally, as we expected, 
CD209_-13Kb and CISH_+16Kb enhancer activities were not influenced by ligand-activated 
RXR (Figure 6B).  
Taken together, these results suggest that the lipid sensing RXR and IL-4/STAT6 signaling 
pathways can interact displaying different modalities (synergistic, potentiating or liganded RXR-
independent) in an enhancer and gene specific manner with each other providing combinatorial 
gene expression and modulating phenotypic properties of human macrophages (Figure 7). These 
observations are integral part of our laboratory’s systematic efforts, to better understand the roles 
of RXRs in the genome-wide organization of nuclear receptor cistromes and the interactions 
between nuclear receptors and other signal-dependent transcription factors in different cell types. 
(Daniel et al., 2014, Simandi, Horvath, Wright et al., 2016, Simandi et al., 2017) Nevertheless, 
the detailed characterization of the interactions between IL-4/STAT6 and liganded RXR 
signaling pathways requires further experimental analysis applying RXR antagonist or deleting 
RXRα and ȕ isoforms in human macrophages. 
 
CONCLUSIONS 
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Taken together, herein we provided and described several novel functional interactions deduced 
from extensive mapping of both cistromic as well as transcriptomic events induced by IL-4 alone 
or in combination with LG268 in primary human macrophage-like cells. These include (i) the 
cistromic maps of PU.1, RXR and STAT6 in primary macrophage like cells, (ii) the cistromic 
overlap between STAT6 and RXR, (iii) the lack of NR motif within these co-peaks, (iv) the gene 
and/or enhancer-specific synergistic and potentiating cross-talk between ligand-acitvated RXR 
and IL-4/STAT6 signaling pathways.  These findings suggest that there is an extensive interplay 
between ligand-activated RXR and IL-4/STAT6 signaling pathways at both the cistromic and 
transcriptomic levels. 
More generally, our results further reinforce the notion that it is likely that the lipid 
microenvironment is insufficient to induce macrophage polarization alone. However it is able to 
modulate IL-4 responsiveness of primary human macrophage-like cells enhancing and potentially 
reinforcing the alternative macrophage polarization cellular phenotype. Therefore, RXR signaling 
may be a potential therapeutic target in alternative macrophage activation-associated diseases 
including parasites infections and tumor development.         
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FIGURE LEGENDS 
 
Figure 1. Schematic representation of the differentiation protocol and the experimental 
design. (A) The differentiation protocol of human CD14+ monocyte derived diffMQ cells as 
described in the Materials and Methods section is shown. (B) Schematic representation of the 
experimental setup for the cistromic and transcriptomic analyses of diffMQ cells.  
 
Figure 2. Identification of novel IL-4 responsive genes in diffMQ cells. (A) RNA expression 
of known human alternative macrophage activation markers in control and IL-4-stimulated 
diffMQ cells. diffMQ cells were treated with IL-4 for 4 hours. The selected markers were 
visualized in the Integrated Genome Viewer (IGV). (B) Heat map showing fold changes of IL-4 
responsive transcripts in unstimulated (ctrl) and IL-4-stimulated (IL-4) diffMQ cells. diffMQ 
cells were treated with IL-4 for 4 hours. (C) Top 10 most significantly enriched biological 
processes within IL-4-regulated genes identified by DAVID Bioinformatics Database. (D) Heat 
map showing RPKM values of the expressed RXR isoforms and their potential hetrodimerization 
partners in unstimulated (ctrl) and IL-4-stimulated (IL-4) diffMQ cells. diffMQ cells were treated 
with IL-4 for 4 hours.   
 
Figure 3. Genome-wide mapping of H3K27Acetylated PU.1, RXR and STAT6 occupied 
regions in diffMQ cells. (A) Venn diagram represents overlapping peaks among 
H3K27Acetylated PU.1, RXR and STAT6 occupied regions. Table contains total number of 
peaks occupied by each transcription factor overall (consensus) or in an active (H3K27Ac 
positive) state. (B) Read distribution plot of ChIP-seq intensities against H3K27Ac, PU.1, RXR 
and STAT6 around the detected PU.1 peaks in 4 Kb window in both control and IL-4-stimulated 
diffMQ cells.  (C) Box plot representation of H3K27Ac marks at the surrounding genomic 
regions of RXR, STAT6 and RXR+STAT6 peaks in in control or IL-4-stimulated diffMQ cells.  
 
Figure 4. Characterization of RXR, STAT6 and RXR-STAT6 peak sets. (A) Genomic 
distribution of RXR, STAT6 and RXR+STAT6 peaks relative to gene coding regions expressed 
as % of total PU.1 positive peak numbers. (B) De novo motif enrichment under RXR, STAT6 
and RXR+STAT6 peaks from ChIP-seq data using HOMER. “Target %” refers to the ratio of the 
peaks having the given motif, and “Bg %” refers to the ratio of a random background. 
 
Figure 5. Identification of IL-4 responsive gene associated RXR, STAT6 and RXR+STAT6 
peaks. (A) Annotation of RXR, STAT6 and RXR+STAT6 peaks of IL-4 responsive genes within 
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± 100Kb distance relative to TSS. (B) Distribution of RXR, STAT6 and RXR+STAT6 peaks 
relative to TSSs of the IL-4-regulated genes. (C) H3K27Ac, PU.1, STAT6 and RXR ChIP-Seq as 
well as RNA-seq signals at select genomic regions in IL-4-stimulated or unstimulated diffMQ 
cells. ChIP-seq and RNA-seq signals for the indicated factors, as well as post-translational 
histone modification and mRNA expression are visualized by the Integrative Genomics Viewer.   
 
Figure 6. Characterization of potential interactions between IL-4/STAT6 and RXR 
signaling pathways at the gene and enhancer levels. (A) qRT-PCR measurement of the 
expression of select mRNAs in vehicle (veh), IL-4 (IL-4/veh), RXR ligand LG268 (LG268) or 
costimulated (IL-4/LG268) monocyte-derived diffMQ cells from two independent human donors 
(D1 and D2). diffMQ cells were treated with IL-4 and LG268 for 4 hours. (B) qRT-PCR 
measurement of eRNA expression at the enhancers of the select IL-4-responsive genes in control 
(veh), IL-4 (IL-4/veh), RXR ligand LG268 (LG268) or costimulated (IL-4/LG268) diffMQ cells. 
diffMQ cells were treated with IL-4 and LG268 for 30, 60 minutes and 4 hours. 
 
Figure 7. Schematic representation of the potential interactions between IL-4/STAT6 and 
ligand-activated RXR signaling pathways in diffMQ cells.  
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